VRTX - Bluebird Bio: Innovative Therapies Monetary Setbacks

2024-01-25 10:57:50 ET

Summary

• More than one year into the Launch of Zynteglo and Skysona, BLUE's sales remain underwhelming.
• The company launched a third gene therapy, Lyfgenia, but faces similar commercialization challenges.
• High treatment costs, limited patient base, outsourced production, long-term follow-up studies, and intensifying competition are all factors that obscure BLUE's path to profitability.

Investment Thesis

Our previous article published last year cautioned that significant financial risks overshadow bluebird bio, Inc.'s ( BLUE ) innovative gene therapies. In early 2023, the Massachusetts-based biotech company launched two orphan drugs: Zynteglo for Transfusion-Dependent B-thalassemia 'TDT' and Skysona for Cerebral Adrenoleukodystrophy 'CALD.' ...

For further details see: